DIMERx Appoints Biotech Leader Sergio Traversa, PharmD, to Board of Directors

SAN FRANCISCO, July 09, 2025 (GLOBE NEWSWIRE) -- DIMERx, Inc., a late-stage clinical biopharmaceutical company developing covalently bonded dimer therapeutics, today announced the appointment of Sergio Traversa, PharmD, as an Independent Director to its Board of Directors, effective June 25, 2025. Dr. Traversa currently serves as CEO of Relmada Therapeutics (Nasdaq: RLMD), a clinical-stage biotechnology company focused on developing transformative therapies for oncology-related and central nervous system co ...